Stockreport

Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly r [Read more]